Mounjaro Tracker App
Precision tracking for dual GIP and GLP-1 receptor agonism. Model tirzepatide's 5-day half-life curve, track the 6-step escalation ladder up to 15 mg, and log blood glucose correlations on iOS.
GLPme is a dedicated Mounjaro tracking app built for the unique pharmacokinetics of tirzepatide's dual GIP and GLP-1 receptor agonism. With a sharper 5-day half-life and a 6-step titration ladder up to 15 mg, Mounjaro requires precise tracking of injection intervals, blood glucose correlations, and dose-spacing maintenance schedules. GLPme runs 100% on-device on iOS with zero subscriptions.
Key takeaways
- Tracks all 6 tirzepatide dose tiers: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
- Models tirzepatide's 5-day elimination half-life (steeper clearance curve than semaglutide).
- Supports extended interval dose-spacing (e.g. 10-day or 14-day maintenance injections).
- Logs glucose readings alongside weekly doses to monitor HbA1c trajectory.
- 100% private, on-device data storage with no account creation or health data tracking.
Why dual GIP/GLP-1 tracking is different
Tirzepatide is not simply a GLP-1 — it is a twincretin that binds both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. In the SURPASS clinical trials, this dual mechanism produced superior HbA1c reductions and weight loss compared to semaglutide, but it also carries distinct pharmacokinetic timing.
Tirzepatide's elimination half-life is approximately 120 hours (5 days) compared to semaglutide's 7 days. This means drug levels clear roughly 30% faster. Patients on Mounjaro often notice appetite and glycemic variability beginning as early as Day 4 or Day 5 post-shot. GLPme graphs your active tirzepatide curve so you know exactly when blood levels are peaking versus troughing.
The 6-step Mounjaro titration ladder
Mounjaro has six distinct dose strengths, escalating in 2.5 mg increments every 4 weeks under clinical supervision:
| Dose | Duration | Clinical Role |
|---|---|---|
| 2.5 mg | Weeks 1–4 | Treatment initiation; tolerance assessment (non-glycemic dose) |
| 5.0 mg | Weeks 5–8 | First therapeutic maintenance dose |
| 7.5 mg | Weeks 9–12 | Intermediate titration step for improved glycemic control |
| 10.0 mg | Weeks 13–16 | Second approved maintenance dose tier |
| 12.5 mg | Weeks 17–20 | Advanced step-up for high metabolic resistance |
| 15.0 mg | Weeks 21+ | Maximum approved therapeutic maintenance dose |
GLPme tracks your calendar date at each step, preventing accidental premature escalation and warning you when a dose step is due for doctor evaluation.
Tracking dose-spacing maintenance (10 to 14 days)
Many patients who achieve their glycemic and weight targets transition to maintenance protocols such as injecting 5 mg or 10 mg every 10 to 14 days instead of every 7 days. Because tirzepatide's half-life is 5 days, calculating steady-state troughs during extended intervals is mathematically complex. GLPme models your exact rolling curve across non-standard injection schedules.
Compounded tirzepatide and single-dose auto-injectors
Commercial Mounjaro in the US ships as single-dose prefilled pens, but millions of patients use compounded tirzepatide in multi-dose vials (frequently 10 mg/mL or 20 mg/mL concentrations). GLPme features a dedicated compounded tirzepatide calculator that translates prescribed milligrams to exact syringe units (e.g. 50 units for 10 mg at 20 mg/mL), eliminating hazardous dosing arithmetic.
Correlating blood glucose with weight trend
Because Mounjaro is prescribed for type 2 diabetes, managing glucose levels is paramount. GLPme lets you log fasting glucose readings alongside your weekly weight and injection logs, revealing how tirzepatide stabilizes insulin sensitivity over time.
Sources
Every figure on this page traces to one of these. Regulatory documents and peer-reviewed primary research only — see our editorial policy for what we accept as a source.
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med, 2021. View source
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med, 2022. View source
- Eli Lilly and Company. Mounjaro (tirzepatide injection) Prescribing Information and Titration Guidelines. View source
- GLP-1 Agonists: What They Are, How They Work & Side Effects. Cleveland Clinic. View source
Download GLPme for Mounjaro on iOS
Model active dual-agonist levels, log fasting glucose, and track your tirzepatide journey with total privacy.
